

RECEIVED
CENTRAL FAX CENTER

2

OCT 10 2006

PTO/GD/31 (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

NOTICE OF APPEAL FROM THE EXAMINER TO THE BOARD OF PATENT APPEALS AND INTERFERENCES		Docket Number (Optional)										
<p>I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <u>10-10-2006</u>.</p> <p>Signature <u>N. Nassief</u></p> <p>Typed or printed name <u>NIDA NASSIEF</u></p>		<p>In re Application of</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td style="width: 40%;">Filed</td> </tr> <tr> <td><u>091944,564</u></td> <td><u>09/04/2001</u></td> </tr> <tr> <td colspan="2" style="text-align: center;">For</td> </tr> <tr> <td style="width: 60%;">Art Unit</td> <td style="width: 40%;">Examiner</td> </tr> <tr> <td><u>1623</u></td> <td><u>Patrick T Lewis</u></td> </tr> </table>	Application Number	Filed	<u>091944,564</u>	<u>09/04/2001</u>	For		Art Unit	Examiner	<u>1623</u>	<u>Patrick T Lewis</u>
Application Number	Filed											
<u>091944,564</u>	<u>09/04/2001</u>											
For												
Art Unit	Examiner											
<u>1623</u>	<u>Patrick T Lewis</u>											
<p>Applicant hereby appeals to the Board of Patent Appeals and Interferences from the last decision of the examiner</p> <p>The fee for this Notice of Appeal is (37 CFR 41.20(b)(1)) <u>\$ 500</u></p> <p><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee shown above is reduced by half, and the resulting fee is: <u>\$ 250</u></p> <p><input type="checkbox"/> A check in the amount of the fee is enclosed.</p> <p><input checked="" type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.</p> <p><input type="checkbox"/> The Director has already been authorized to charge fees in this application to a Deposit Account. I have enclosed a duplicate copy of this sheet.</p> <p><input type="checkbox"/> The Director is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. _____ . I have enclosed a duplicate copy of this sheet.</p> <p><input type="checkbox"/> A petition for an extension of time under 37 CFR 1.136(a) (PTO/SB/22) is enclosed.</p>												
<p>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p> <p>I am the <u>N. Nassief</u> <input checked="" type="checkbox"/> applicant/inventor. <input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96) <input type="checkbox"/> attorney or agent of record. Registration number _____ <input type="checkbox"/> attorney or agent acting under 37 CFR 1.34 Registration number if acting under 37 CFR 1.34. _____</p> <p><u>NIDA NASSIEF</u> Typed or printed name <u>+974 4650 664</u> Telephone number <u>10-10-2006</u> Date</p>												
<p>NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.</p> <p><input type="checkbox"/> Total of <u>2</u> forms are submitted. credit card payment will arrive by mail</p>												

This collection of information is required by 37 CFR 41.31. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11, 1.14 and 41.6. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

3

RECEIVED
CENTRAL FAX CENTER

**U. S. Patent and Trademark Office
Board of Appeal and Interferences
Fax No.: + 571-273-8300**

OCT 10 2006

My Reference: Patent Application Number: 09/944,564

Date: October 10, 2006
Total number of pages: 10
Annexes will be sent by mail

Fax letter

Notice of Appeal From the Examiner to the Board of Appeal and Interferences
Submitted in
Response to Office Action dated 07/11/2006 (Final Rejection)

Dear Sir:

In response to the above-identified final rejection of my patent application claims 25-27, may I kindly submit the following response:

- 1- By submitting a Notice of Appeal From the Examiner to the Board of Appeal and Interferences [Form: PTO/SB/31 (07-06)].
- 2- Payment by Credit Card. Form PTO-2038 is attached.
- 3- Objection to the Examiner decision by submitting further evidence from medical textbooks clarifying the point of dispute with the examiner; in relation to the definition of asthma and asthmatic bronchitis, and differentiating them as unrelated separate medical entities, thus rendering my claims in the use of glycophosphopeptical in the treatment of asthma patentable and valid.
- 4- Amendment of claim 25, currently reads as "25. (New) A pharmaceutical composition consisting essentially of glycophosphopeptical for oral administration for the treatment of allergy and asthma in dosage and duration which is effective to....etc"; may I kindly request separation of the use of glycophosphopeptical in the treatment of allergy from its use in the treatment of asthma. Discussion of the use in the treatment of allergy are part of the response to Office Action dated

Detailed response will follow.

Thank you for considering my appeal.

Best regards

The Inventor
Nida Nasif

Application/Control No.: 09/944,564
Inventor: Nida Nassief

Page 1

Examiner: Patrick T. Lewis
Board of Appeal and Interference

Notice of Appeal from the Examiner to the Board of Appeal and Interferences

Submitted in Response to Office Action dated 07/11/2006 (Final Rejection)

Date: October 10, 2006

Dear Sir:

Please fid following detailed response:

Rejection of Record Set Forth in the Office Action Dated November 21,2005

In this Office Action the Examiner have rejected claim 25 - 27 of my patent application number 09/944,564. Currently I am defending claim 25 that reads as follows:

25. (New) A pharmaceutical composition consisting essentially of glycophosphopeptical for oral administration for the treatment of allergy and asthma in dosage and duration which is effective to:

- i- Switch-off the airway eosinophilic inflammation.
- ii- Reduce mucus secretion.
- iii- Reduce symptom score significantly.
- iv- Restore airway patency as measured by Pulmonary Function Test.

The cause of rejection

From the above identified Office Action pages 3 - 4:

7. Claims 25-27 are rejected under 35 U. S. C. 102(b) as being anticipated by Sanchez Palacios A. et. al. Allergol Immunopathos (Madr) (1992), Vol 20 (1), pages 35-39 (Sanchez).

Sanchez discloses the use of Immunoferon (AM3) in the treatment of childhood infectious respiratory pathology. To assess the immunoclinical effectiveness of a biologic response immunomodulator, glycophosphopeptide (AM3) was administered to 20 children with asthmatic bronchitis. The children received 2 envelops (1gm) daily for 4 months. The clinical and immunological parameters assessed were: cough, dyspnoea, expectoration, frequency and intensity of bronchospasm, time of administration of the symptomatic medication, and the delayed cutaneous cells response by means of the intradermal reaction of 5 antigens: Immunoferon reduced the symptoms, the intensity and frequency of the bronchospasm, and the symptomatic medication.

8. Aplicant's argument filed April 12, 2006 has been fully considered but they are not persuasive. Aplicant's argue that Sanchez is referring to infectious respiratory pathology (asthmatic bronchitis) which is not bronchial asthma which is allergic or atopic.

Aplicant's arguments have been considercd but are not deemed germane. Sanchez teaches the use of glycophosphopeptide for treating asthmatic bronchitis. It was well known in the art at the time of the invention that asthmatic bronchitis is a condition in which the airways in the lung are obstructed due to both persistent asthma and bronchitis. Thus, the patient population treated by the method of Sanchez embraces asthma patients and therefore meets the limitation of the instantly claimed invention.

Application/Control No.: 09/944,564
 Inventor: Nida Nassief

Page 2

Examiner: Patrick T. Lewis
 Board of Appeal and Interference

Appeal From the Examiner to the Board of Appeal and Interferences

What is my dispute difference of opinion) with the Examiner in relation to Office Action dated
 07/11/2006

In this appeal, may I kindly request the Board of Appeal to consider the following two requests:

First: I am still arguing that asthma and asthmatic bronchitis are two separate unrelated diseases and that my claim rejection was brought up by confusion in the name between the old term of asthmatic bronchitis and asthma. Accordingly the use of glycophosphopeptidal in the treatment of asthma in my patent is novel and kindly requesting its allowance.

Second: Claim 25 reads as "A pharmaceutical composition consisting essentially of glycophosphopeptidal for oral administration for the treatment of allergy and asthmaetc". I am arguing that the pharmaceutical composition for the treatment of "allergy" as a group of diseases referred to separately in the patent application, under description of the invention, with enablement and previous clarification in my reply to the Office Action filed on Aug 2004 with X-ray films clarifying its unique outcome of early clinical testing , and will be detailed later, have been forgotten and overlooked. May I kindly request the allowance of this claimed invention.

In this reply, references to the standard teaching of medical textbooks are made for detailed description of asthmatic bronchitis. Selected chapters are photocopied, and the relevant paragraphs are underlined in order to clarify the source of confusion in the name, the differentiating clinical features, and the correlation between asthmatic bronchitis and asthma. I am trying to keep the text minimal, but excuse me for placing some paragraphs and sentences of secondary importance to keep the continuity of the reply.

Asthma is currently an international enigma with increasing incidence and uncontrolled patients. According to medical reports released during 2006 from the "Global Initiative Of Asthma" that will be included in the mail copy of this Response and Appeal.

Detailed Appeal / First

Claim 25 in relation to "A pharmaceutical composition consisting essentially of glycophosphopeptidal for oral administration for the treatment of asthma"

My argument filed April 12, 2006 was that the Sanchez had excluded cases of asthma in patients selection as described in page 36 column 1 of the article as follows:

"MATERIAL Y METODOS

Pacientes. Se seleccionaron 40 ninos no atopicos con clinica respiratoria infecciosa de bronquitis espastica y/o asmatica con pruebas cutaneas a neumoallergenos negativas e IgE total normal.

6

Application/Control No.: 09/944,564
Inventor: Nida Nassief

Page 3

Examiner: Patrick T. Lewis
Board of Appeal and Interference

May I add to my argument filed April 12, 2006 that referring to the title of the article by Sanchez which reads as "Valoración clínica immunológica de un modificador de la respuesta biológica, AM3, en el tratamiento de la patología respiratoria infectiosa infantil", this description fits the condition of asthmatic bronchitis "bronchiolitis" as will follow, but not asthma.

In the Examiners Office Action dated 07/11/2006, page 4, line 7, he have the following comment "It was well known in the art at the time of the invention that asthmatic bronchitis is a condition in which the airways in the lungs are obstructed due to both persistent asthma and bronchitis." My reply is that "The term bronchiolitis was first used by Engle and Newns in 1940, bronchiolitis appears to have been born from a long lineage of confusing sobriquets, including "asthmatic bronchitis." As will be described below under the title "Bronchiolitis" page 5 of this report. Therefore at the time of filing my invention it was well known that asthma and asthmatic bronchitis are two separate diseases.

Most important, to support my argument further, I am submitting new evidence from the standard teaching of medical textbooks that clarifies the point that asthma previously was used to indicate "shortness of breath" as in the case of the term "cardiac asthma" that is used to denote shortness of breath in heart failure (Annex II). Furthermore the correlation between asthma and asthmatic bronchitis; selected from the textbook of Principles and Practice of Infectious Diseases 2005 (Annex III), asthmatic bronchitis is currently named bronchiolitis. The term bronchiolitis was first used by Engle and Newns in 1940 for the lower respiratory tract disease observed in young infants. The term bronchiolitis appears to have been born from a long lineage of confusing sobriquets, including "acute catarrhal bronchitis," "interstitial bronchopneumonia," "spastic bronchopneumonia," "capillary or obstructive bronchiolitis," and "asthmatic bronchitis." And that "We are dealing with two separate diseases that may coexist in an infant, and that children with bronchiolitis in infancy have no increased risk of asthma by the time they reach adolescence." This will be detailed further in the following text. May I kindly request consideration of this new evidence and other reference in the text and allow my claimed invention.

Confusing medical terms using asthma

The term asthma, historically, is used to designate any disease characterized by "asthma-like symptoms", in patients complaining of dyspnoea, wheeze, cough and sputum. Those diseases are unrelated to the disease entity of current asthma; examples are 1- "cardiac asthma" and 2- "asthmatic bronchitis".

1- Cardiac Asthma

The clinical manifestations of heart failure includes respiratory disturbances as dyspnoea and paroxysmal nocturnal dyspnoea; this term refers to attacks of sever shortness of breath and coughing that generally occur at night. Cardiac asthma is closely related to paroxysmal nocturnal dyspnoea and nocturnal cough and is characterized by wheezing secondary to bronchospasm-most prominent at night.

Application/Control No.: 09/944,564
Inventor: Nida Nassief

Page 4

Examiner: Patrick T. Lewis
Board of Appeal and Interference

Annex II - Part VIII Disorders of the Cardiovascular System: page 1370. HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, 16th Edition (2005) Mc Graw-Hill

2- Bronchiolitis (Asthmatic Bronchitis)

Exact definition of asthmatic bronchitis is available from a textbook of "Principles and Practice of Infectious Diseases", selected paragraphs follows indicates that we are dealing with two separate diseases that may coexist in an infant. The following statements constitute a reply to the point raised by the examiner::

Page 812, column 2: "Bronchiolitis is an acute viral lower respiratory tract illness that occurs during the first 2 years of life. The illness also has been called "wheezy bronchitis" and "asthmatic bronchitis". Whatever term is applied, the syndrome is caused primarily by viral infections. The characteristic clinical manifestations include an acute onset of wheezing and hyperinflation, most commonly associated with cough, rhinorrhea, tachypnoea (increased respiratory rate) and respiratory distress."

"The term bronchiolitis appears to have been born from a long lineage of confusing sobriquets, including "acute catarrhal bronchitis," "interstitial bronchopneumonia," "spastic bronchopneumonia," "capillary or obstructive bronchiolitis," and "asthmatic bronchitis." Bronchiolitis, however, did not become recognized as a distinct entity until the 1940s."

In page 814, column 1 under the term Pathophysiology "The term bronchiolitis was first used by Engle and Newns in 1940 for the lower respiratory tract disease observed in young infants that tend to be sever and often fatal. The virus initially replicates in the epithelium of the upper respiratory tract, but in the young infant it tends to spread rapidly to the lower tract airways."

"Inflammatory changes of various severity are observed in most small bronchi and bronchioles. The inflammation and edema make the small-lumen airways in infants particularly vulnerable to obstruction. Thus, although airflow is impeded during both inspiration and expiration, the latter is more affected and prolonged."

In the first column, last paragraph in page 815, under the title of "Pathophysiology": "Clarifying the relationship between bronchiolitis and subsequent asthma is complicated by confusion about